Clearside biomedical announces positive topline results from odyssey phase 2b trial of suprachoroidal cls-ax in wet amd achieving all primary and secondary outcomes

- maintained stable visual acuity and anatomical control over 9 months - - positive safety profile with no ocular or treatment-related serious adverse events - - 67% of cls-ax participants did not require any additional treatment up to 6 months - - reduced treatment burden by 84% over 6 months - - webcast and conference call today at 8:00 a.m. et with management and  key opinion leader and board-certified retinal specialist, roger goldberg, m.d.
CLS Ratings Summary
CLS Quant Ranking